Vir Biotechnology 거래 VIR

VirBiotechnology 실시간 차트

상품 기초

Weekly Search
Weekly
Daily
날짜 종료 변경 변동(%) 열기 높음 낮음

VirBiotechnology news

최신 뉴스

더 보기
Emma Rose 2025 Sep 19, 15:20

Federal Reserve Reform on the Horizon: Price Stability Act Sparks Debate on Central Bank's Mission

Ava Grace 2025 Sep 19, 14:20

Market Review: Fed Rate Cut and Global Economic Trends

Noah Lee 2025 Sep 19, 11:20

US Senators Target Russian Energy Exports with 'Shadow Fleet' Sanctions

Sophia Claire 2025 Sep 19, 04:20

Bank of Japan Holds Rates Steady, Plans to Start Selling ETFs

Liam James 2025 Sep 18, 15:20

Hong Kong Gold Theft Recovered: A Sign of a Growing Global Trend?

Ava Grace 2025 Sep 18, 15:20

US Initial Jobless Claims Fall: A Rebound or a Sign of Stability?

Sophia Claire 2025 Sep 18, 14:20

White House Reacts to Fed Rate Cut: Implications and Analysis

Sophia Claire 2025 Sep 18, 13:20

Swiss Gold Exports to US Plunge Amid Tariff Confusion

정보

스프레드

0.05

스프레드(%)

0.9728 %

레버리지

1:10

익일 이자 매수

-0.0597 %

익일 이자 매도

-0.0292 %

통화

USD

거래 시간

시장 폐장

월요일

13:31 - 19:59

화요일

13:31-19:59

수요일

13:31-19:59

목요일

13:31-19:59

금요일

13:31-19:59

분석 및 통계

열기

---

이전 종가

---

52주 최고/최저

--- – ---

시가총액

719587072

발행 주식 수

138916426

수익 날짜 (다음)

0000-00-00

배당수익률

배당락일

예상 연간 배당금

0

예상 연간 배당수익률

0

EPS

-4.01

이 상품에 대해 자세히 알아보기

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

latest_education_articles

더 보기
Trustpilot